Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty

This study has been completed.
Glaucoma Research Society of Canada
Information provided by (Responsible Party):
Dr. Robert Campbell, Queen's University Identifier:
First received: June 9, 2007
Last updated: September 21, 2015
Last verified: September 2015
The type of anti-inflammatory medication used post selective laser trabeculoplasty (SLT) may have an impact on the intra-ocular pressure (IOP) lowering effect of SLT. This study will evaluate the IOP lowering effect of SLT following the topical administration of one of the following: prednisolone 1%, ketorolac 0.5% or artificial tears.

Condition Intervention
Primary Open Angle Glaucoma
Pseudoexfoliation Glaucoma
Drug: prednisolone 1%
Drug: ketorolac 0.5%
Drug: Artificial Tears (Methyl cellulose drops)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study

Resource links provided by NLM:

Further study details as provided by Queen's University:

Primary Outcome Measures:
  • Intraocular pressure lowering effect [ Time Frame: 1 hour, 2 days, 1 month, 3 months, 6 months and 1 year ]

Secondary Outcome Measures:
  • intraocular pressure elevation [ Time Frame: 1 hour, 2 days, 1 month ]

Enrollment: 120
Study Start Date: January 2007
Study Completion Date: December 2014
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Prednisolone 1% eye drop
Drug: prednisolone 1%
eye drop once in each eye treated, 4 times / day for 5 days post-laser
Active Comparator: 2
ketorolac 0.5% eye drop
Drug: ketorolac 0.5%
eye drop once in each eye treated, 4 times / day for 5 days post-laser
Other Name: Acular
Placebo Comparator: 3
Artificial Tears (methyl cellulose eye drop)
Drug: Artificial Tears (Methyl cellulose drops)
eye drop once in each eye treated, 4 times / day for 5 days post-laser
Other Name: Refresh Tears

Detailed Description:
Patients who have been chosen to undergo SLT for glaucoma will be randomized to receive one of prednisolone 1%, ketorolac 0.5% or artificial tears four times a day for 5 days following administration of the laser treatment. The IOP will be measured at various time points following SLT: 1 hour, 2 days, 1 week, 1 month, 3 months, 6 months, and 1 year.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • primary open angle glaucoma, pseudo exfoliation glaucoma

Exclusion Criteria:

  • previous incisional glaucoma surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00485108

Canada, Ontario
Queen's University
Kingston, Ontario, Canada
Sponsors and Collaborators
Queen's University
Glaucoma Research Society of Canada
Principal Investigator: Rob J Campbell, MD, MSc Queen's University
Study Director: Delan Jinapriya, MD Queen's University
  More Information

Responsible Party: Dr. Robert Campbell, Assistant Professor, Queen's University Identifier: NCT00485108     History of Changes
Other Study ID Numbers: DJ1
Study First Received: June 9, 2007
Last Updated: September 21, 2015

Keywords provided by Queen's University:
primary open angle glaucoma
pseudoexfoliation glaucoma
selective laser trabeculoplasty
intra ocular pressure
anti-inflammatory therapy
prednisolone acetate 1%
ketorolac tromethamine 0.5%

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Exfoliation Syndrome
Ocular Hypertension
Eye Diseases
Iris Diseases
Uveal Diseases
Ketorolac Tromethamine
Prednisolone acetate
Methylprednisolone acetate
Anti-Inflammatory Agents
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Ophthalmic Solutions
Lubricant Eye Drops
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 24, 2017